Paper40284397
Nanocrystallization Effectively Improves the Oral Efficacy of an Antileishmanial Chalcone.
Borsodi MPG and 9 others. Pharmaceutics, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Nanocrystallization Effectively Improves the Oral Efficacy of an Antileishmanial Chalcone. Papers, record 40284397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40284397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanocrystallization Effectively Improves the Oral Efficacy of an Antileishmanial Chalcone.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| E-26/201.384/2022 (JCNE) and E26/010.002426/2019 (REDE SAÚDE) | Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) | PubMed |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12615413 | Formulation of amphotericin B as nanosuspension for oral administration. | Int J Pharm | 2003 | https://conductscience.org/library/papers/12615413 | PubMed |
| 2 | 23383426 | Strategies to address low drug solubility in discovery and development. | Pharmacol Rev | 2013 | https://conductscience.org/library/papers/23383426 | PubMed |
| 3 | 38543222 | Design Space and Control Strategy for the Manufacturing of Wet Media Milled Drug Nanocrystal Suspensions by Adopting Mechanistic Process Modeling. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38543222 | PubMed |
| 4 | 25860834 | pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. | J Med Chem | 2015 | https://conductscience.org/library/papers/25860834 | PubMed |
| 5 | 10223942 | Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10223942 | PubMed |
| 6 | 39608687 | Brominated chalcones as promising antileishmanial agents. | Bioorg Med Chem Lett | 2025 | https://conductscience.org/library/papers/39608687 | PubMed |
| 7 | 26998867 | Diclofenac acid nanocrystals as an effective strategy to reduce in vivo skin inflammation by improving dermal drug bioavailability. | Colloids Surf B Biointerfaces | 2016 | https://conductscience.org/library/papers/26998867 | PubMed |
| 8 | 23985066 | Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. | Parasitology | 2014 | https://conductscience.org/library/papers/23985066 | PubMed |
| 9 | 29263064 | Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29263064 | PubMed |
| 10 | 28668673 | The chemotherapeutic potential of chalcones against leishmaniases: a review. | Int J Antimicrob Agents | 2018 | https://conductscience.org/library/papers/28668673 | PubMed |
| 11 | 23415952 | In vitro and in vivo models for the study of oral delivery of nanoparticles. | Adv Drug Deliv Rev | 2013 | https://conductscience.org/library/papers/23415952 | PubMed |
| 12 | 16386424 | Synthesis of chalcone analogues with increased antileishmanial activity. | Bioorg Med Chem | 2006 | https://conductscience.org/library/papers/16386424 | PubMed |
| 13 | 32364107 | Single-dose treatment for cutaneous leishmaniasis with an easily synthesized chalcone entrapped in polymeric microparticles. | Parasitology | 2020 | https://conductscience.org/library/papers/32364107 | PubMed |
| 14 | 31766540 | Formation of Prenylated Chalcone Xanthohumol Cocrystals: Single Crystal X-Ray Diffraction, Vibrational Spectroscopic Study Coupled with Multivariate Analysis. | Molecules | 2019 | https://conductscience.org/library/papers/31766540 | PubMed |
| 15 | 25455766 | Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability. | Int J Pharm | 2014 | https://conductscience.org/library/papers/25455766 | PubMed |
| 16 | 23224077 | Reactivity assessment of chalcones by a kinetic thiol assay. | Org Biomol Chem | 2013 | https://conductscience.org/library/papers/23224077 | PubMed |
| 17 | 34780470 | Chalcones identify cTXNPx as a potential antileishmanial drug target. | PLoS Negl Trop Dis | 2021 | https://conductscience.org/library/papers/34780470 | PubMed |
| 18 | 29326082 | Pharmaceutical nanocrystals: production by wet milling and applications. | Drug Discov Today | 2018 | https://conductscience.org/library/papers/29326082 | PubMed |
| 19 | 28732905 | Preparation of fungus-derived chitin nanocrystals and their dispersion stability evaluation in aqueous media. | Carbohydr Polym | 2017 | https://conductscience.org/library/papers/28732905 | PubMed |
| 20 | 22355202 | Use of in vivo and in vitro systems to select Leishmania amazonensis expressing green fluorescent protein. | Korean J Parasitol | 2011 | https://conductscience.org/library/papers/22355202 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40284397
GET https://conductscience.org/api/papers/v1/40284397/references?page=2